Immuno-PET Shows Promise for Detecting and Treating Pancreatic Tumors

LW Newsfeed
Pancreatic cancer is associated with bleak five-year survival rates and limited treatment options, but new research is offering hope.

A first-in-human study presented at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) demonstrates the feasibility and safety of the novel human monoclonal antibody HuMab-5B1 with highly specific targeting for the cancer antigen (CA) 19-9, which is expressed on pancreatic tumors and a variety of other malignancies, including small cell lung cancer and tumors of the gastrointestinal system. Read more . . .

 

 

image_printPrint Page

Conversation